What are the current treatment recommendations for myocarditis?

Current Treatment Recommendations for Myocarditis

All patients with confirmed myocarditis should be hospitalized for monitoring and supportive care, with treatment stratified by severity: mild-to-moderate cases require hospitalization ideally at advanced heart failure centers, while fulminant myocarditis demands management at centers with mechanical circulatory support capabilities. 1

Initial Management and Risk Stratification

The cornerstone of myocarditis treatment is supportive care tailored to clinical severity 2. Approximately 75% of hospitalized patients have an uncomplicated course with near-zero mortality, while those presenting with acute heart failure or ventricular arrhythmias face a 12% rate of death or transplant, and hemodynamically unstable patients requiring mechanical support have a 28% mortality or transplant rate at 60 days 2.

Hemodynamic Support

For the 2-9% of patients with hemodynamic instability and inadequate end-organ perfusion:

• Inotropic agents should be initiated
• Mechanical circulatory support (such as extracorporeal life support) should be deployed early to facilitate myocardial recovery 2
• These patients require management at specialized centers with advanced heart failure expertise 1

Heart Failure Management

Guideline-directed medical therapy (GDMT) for heart failure should be initiated during hospitalization and continued after discharge 1. This applies to all patients with reduced ejection fraction, regardless of etiology.

Immunosuppressive Therapy: A Targeted Approach

The use of immunosuppression requires careful patient selection based on specific clinical scenarios:

Clear Indications for Corticosteroids:

1. COVID-19 myocarditis with pneumonia requiring supplemental oxygen: corticosteroids are recommended 1

2. Hemodynamically compromised COVID-19 myocarditis or MIS-A: intravenous corticosteroids may be considered 1

3. Biopsy-proven specific histologic patterns:

   • Eosinophilic myocarditis
   • Giant cell myocarditis
   • Severe myocardial infiltrates on endomyocardial biopsy 1, 2

4. Myocarditis secondary to systemic autoimmune disorders (e.g., systemic lupus erythematosus) 2

5. Fulminant myocarditis: empiric corticosteroids may be considered, balanced against infection risk 1

Important Caveat:

For typical viral myocarditis without the above features, immunosuppression is NOT routinely recommended 2. The evidence supporting corticosteroid use in most myocarditis cases is anecdotal, and randomized trials are lacking 2.

Pericardial Involvement

When pericardial inflammation coexists (myopericarditis):

• NSAIDs, colchicine, and/or prednisone are reasonable treatment options 1
• Recent advances include interleukin-1 (IL-1) inhibitors for recurrent/refractory pericarditis 3, 4

Exercise Restriction

Complete exercise abstinence for 3-6 months is recommended for clinical myocarditis 1. Return-to-play decisions require:

• Absence of cardiopulmonary symptoms
• Resolution of myocardial injury markers
• Normalized left ventricular systolic function
• No spontaneous or inducible arrhythmias on monitoring and stress testing 1

Reassessment with repeat cardiac MRI is reasonable to document resolution of inflammation before clearing patients for exercise 1.

Follow-Up and Monitoring

• Cardiology consultation is mandatory for rising troponin and/or ECG/echocardiographic abnormalities 1
• Cardiac MRI is recommended in hemodynamically stable patients for definitive diagnosis 1
• Serial imaging may be needed to document resolution, particularly in athletes or those seeking return to strenuous activity 1

Key Clinical Pitfalls

1. Avoid empiric immunosuppression in typical viral myocarditis without specific indications—this practice lacks evidence and may worsen outcomes 2

2. Don't discharge patients prematurely: even mild-to-moderate myocarditis warrants inpatient monitoring given unpredictable risk of arrhythmias and hemodynamic deterioration 1

3. Balance infection risk: when considering corticosteroids for fulminant cases, ensure adequate infectious workup and weigh risks carefully 1

4. Recognize that most treatment recommendations derive from expert opinion rather than high-quality randomized trials, necessitating individualized risk-benefit assessment 2, 5

Etiology-Specific Considerations

The 2022 ACC guidelines 1 focus heavily on COVID-19-related myocarditis, but the principles apply broadly. The critical distinction is identifying virus-negative cases with depressed cardiac function or underlying autoimmune disease, where immunosuppression may be beneficial 2. This often requires endomyocardial biopsy for definitive etiologic diagnosis when targeted therapy is being considered 5, 6.